This month, the Securities and Exchange Commission announced that the Boston-based Pharmaceutical company Alexion Pharmaceuticals had agreed to pay more than $21 million to resolve claims it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act. The SEC’s order shows that two Alexion subsidiaries made payment to foreign… Continue reading Alexion Pharmaceuticals Charged With FCPA Violations